| Dr Brooke Nicole Maylie, MD, MPH | |
|
1500 Nw Bethany Blvd, Suite 240, Beaverton, OR 97006-5208 | |
| (503) 644-7300 | |
| (503) 641-5179 |
| Full Name | Dr Brooke Nicole Maylie |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 1500 Nw Bethany Blvd, Beaverton, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922399161 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brooke Nicole Maylie, MD, MPH 1500 Nw Bethany Blvd, Suite 240, Beaverton, OR 97006-5208 Ph: (503) 644-7300 | Dr Brooke Nicole Maylie, MD, MPH 1500 Nw Bethany Blvd, Suite 240, Beaverton, OR 97006-5208 Ph: (503) 644-7300 |
News Archive
In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers at NYU Langone Medical Center report that they have identified a possible new drug target for treating the disease.
SANUWAVE, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled "Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells" were presented at the 2009 International Bone-Tissue-Engineering Congress ("Bone-Tec") in Hannover, Germany, which was held October 9-11, 2009.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Leading preventive health care researchers, physicians and executives assembled at U.S. Preventive Medicine® Friday to outline their vision for advancing evidence-based prevention in health care.
Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology
› Verified 5 days ago
David P. Ushman, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 4855 Sw Western Ave, Beaverton, OR 97005 Phone: 503-520-4897 | |
Dr. Adrianne Cheryl Feldstein, M.D. Preventive Medicine Medicare: Medicare Enrolled Practice Location: 4855 Sw Western Ave, Beaverton, OR 97005 Phone: 503-643-7565 | |
Brent T Burton, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1865 Nw 169th Place, Suite 201, Beaverton, OR 97006 Phone: 503-690-9660 Fax: 503-690-4494 |